Posted by Michael Wonder on 19 Jan 2026
Eylea 8 mg approved in the EU for third retinal indication
16 January 2026 - The European Commission has granted marketing authorisation in the EU for Eylea™ 8 mg (aflibercept 8 mg, 114.3 mg/ml solution for injection) for the treatment of patients with visual impairment due to macular oedema following retinal vein occlusion including branch, central and hemiretinal vein occlusion.
Retinal vein occlusion is the third indication for Eylea 8 mg.
